Clinical trial
Phase 3, Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
NCT05881382 is registered in ClinicalTrials.gov with Recardio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3, Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
- Lead sponsor
- Recardio, Inc.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 30, 2023
- Completion date
- September 30, 2025
- Enrollment
- 4,100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.